RT @maciejbanach
The #CLEAROutcomes study CLEARly showed that for high and very high risk #patients even relatively small reduction of #LDLC (21.1%) might be linked to significant reduction of #CVD #outcomes, with the largest attention especially in fatal and non-fatal #MI https://www.sciencedirect.com/science/article/pii/S0033062023000269… https://twitter.com/i/web/status/1632935850144137219

Stopping in to congratulate @shelbyK88 and Michelle Lim PA-C on @EsperionInc #ClearOutcomes Trial.

Why we #acc23. Celebrate successes for therapeutics

RT @SABOURETCardio
Do you speak #lipids ? #CLEAROutcomes is online. A new validated option for #Statins intolerance. Obviously better in fixed combination with #Ezetimibe. Proven efficacy on #MACE. Expected and confirmed benefits according to magnitude of decrease/time exposure

Cardiomastodon @VietHeartPA #clearoutcomes Trial what will we find out?
🫀up to 20% reported #statin intolerance (choice not to use)
🫀prodrug - activated in liver, low to no peripheral tissue effect (⬇️mm aches)
🫀4pt- 3pt- MACE
🫀1°&2° populations
#acc23
https://twitter.com/vietheartpa/status/1632045600391811077?s=61&t=Yz-0chnQVfpDSt8bfrGiCw

#clearoutcomes
🫀subgroups - yay benefit in women
🫀benefit seen in 1° 👀👍🏾 as well as 2°
🫀benefit in diabetes 🙌🏾🙌🏾

Important CVOT adding #BempedoicAcid into the hall of MACE reducing #LLT.
#acc23 #HeartPA #PhysicianAssociate

#clearoutcomes
🫀N~14k, 70% 2°, 30% 1°
🫀~22%ish ⬇️LDL-C and ⬇️hsCRP
🫀RRR 13% 1° MACE endpt
🫀RRR 15% 3-pt MACE
#acc23

#clearoutcomes what will we find out?
🫀up to 20% reported statin intolerance (choice not to use)
🫀prodrug - activated in liver, low to no peripheral tissue effect (⬇️mm aches)
🫀4pt- 3pt- MACE
🫀1°&2° populations
#acc23

Wow. Folks truly want to hear the #LBCT #ClearOutcomes bempedoic acid this am!!!

#acc23